FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4281715808> ?p ?o ?g. }

• W4281715808 endingPage "757" @default.
• W4281715808 startingPage "747" @default.
• W4281715808 abstract "This Phase 1/2 study (NCT02349633) explored the safety and antitumor activity of PF-06747775 (oral, third-generation epidermal growth factor receptor [EGFR] tyrosine kinase inhibitor) in patients with advanced non-small cell lung cancer after progression on an EGFR inhibitor.Phase 1 was a dose-escalation study of PF-06747775 monotherapy (starting dose: 25 mg once daily [QD]). Phase 1b/2 evaluated PF-06747775 monotherapy at recommended Phase 2 dose (RP2D; Cohort 1); PF-06747775 200 mg QD plus palbociclib (starting dose: 100 mg QD orally; Cohort 2A); and PF-06747775 monotherapy at RP2D in a Japanese lead-in cohort.Sixty-five patients were treated. Median treatment duration was 40.1 weeks. Monotherapy maximum tolerated dose was not determined. Two patients in Cohort 2A had dose-limiting toxicities. The monotherapy RP2D was estimated to be 200 mg QD. Most frequently reported adverse events (AEs) were diarrhea (69.2%), paronychia (69.2%), and rash (60.0%). Most AEs were grades 1-3. Overall, objective response rate (90% confidence interval [CI]) was 41.5% (31.2-52.5%). Median (range) duration of response was 11.09 (2.70-34.57) months. Median progression-free survival (90% CI) was 8.1 (5.4-23.3) months.PF-06747775 had a manageable safety profile and the study design highlights important considerations for future anti-EGFR agent development." @default.
• W4281715808 created "2022-06-13" @default.
• W4281715808 creator A5019037704 @default.
• W4281715808 creator A5027053214 @default.
• W4281715808 creator A5028192791 @default.
• W4281715808 creator A5032052889 @default.
• W4281715808 creator A5034777017 @default.
• W4281715808 creator A5043802956 @default.
• W4281715808 creator A5043862738 @default.
• W4281715808 creator A5047405869 @default.
• W4281715808 creator A5055022403 @default.
• W4281715808 creator A5061648315 @default.
• W4281715808 creator A5064697305 @default.
• W4281715808 creator A5078287634 @default.
• W4281715808 creator A5078629724 @default.
• W4281715808 date "2022-06-03" @default.
• W4281715808 modified "2023-10-01" @default.
• W4281715808 title "A phase 1b/2 study of PF-06747775 as monotherapy or in combination with Palbociclib in patients with epidermal growth factor receptor mutant advanced non-small cell lung cancer" @default.
• W4281715808 cites W2076178766 @default.
• W4281715808 cites W2081801534 @default.
• W4281715808 cites W2127357802 @default.
• W4281715808 cites W2128385295 @default.
• W4281715808 cites W2154149901 @default.
• W4281715808 cites W2337507927 @default.
• W4281715808 cites W2536396512 @default.
• W4281715808 cites W2549006812 @default.
• W4281715808 cites W2560717039 @default.
• W4281715808 cites W2568710896 @default.
• W4281715808 cites W2591118779 @default.
• W4281715808 cites W2597231917 @default.
• W4281715808 cites W2898540989 @default.
• W4281715808 cites W2979930936 @default.
• W4281715808 cites W2999203985 @default.
• W4281715808 cites W3001408868 @default.
• W4281715808 cites W3032812050 @default.
• W4281715808 cites W3043371895 @default.
• W4281715808 cites W3112025484 @default.
• W4281715808 cites W3113041077 @default.
• W4281715808 cites W3185315144 @default.
• W4281715808 cites W3192493086 @default.
• W4281715808 doi "https://doi.org/10.1080/13543784.2022.2075341" @default.
• W4281715808 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/35657653" @default.
• W4281715808 hasPublicationYear "2022" @default.
• W4281715808 type Work @default.
• W4281715808 citedByCount "3" @default.
• W4281715808 countsByYear W42817158082023 @default.
• W4281715808 crossrefType "journal-article" @default.
• W4281715808 hasAuthorship W4281715808A5019037704 @default.
• W4281715808 hasAuthorship W4281715808A5027053214 @default.
• W4281715808 hasAuthorship W4281715808A5028192791 @default.
• W4281715808 hasAuthorship W4281715808A5032052889 @default.
• W4281715808 hasAuthorship W4281715808A5034777017 @default.
• W4281715808 hasAuthorship W4281715808A5043802956 @default.
• W4281715808 hasAuthorship W4281715808A5043862738 @default.
• W4281715808 hasAuthorship W4281715808A5047405869 @default.
• W4281715808 hasAuthorship W4281715808A5055022403 @default.
• W4281715808 hasAuthorship W4281715808A5061648315 @default.
• W4281715808 hasAuthorship W4281715808A5064697305 @default.
• W4281715808 hasAuthorship W4281715808A5078287634 @default.
• W4281715808 hasAuthorship W4281715808A5078629724 @default.
• W4281715808 hasBestOaLocation W42817158081 @default.
• W4281715808 hasConcept C121608353 @default.
• W4281715808 hasConcept C126322002 @default.
• W4281715808 hasConcept C143998085 @default.
• W4281715808 hasConcept C197934379 @default.
• W4281715808 hasConcept C2775930923 @default.
• W4281715808 hasConcept C2776256026 @default.
• W4281715808 hasConcept C2776999253 @default.
• W4281715808 hasConcept C2778496288 @default.
• W4281715808 hasConcept C2778570526 @default.
• W4281715808 hasConcept C2779438470 @default.
• W4281715808 hasConcept C2779744173 @default.
• W4281715808 hasConcept C29730261 @default.
• W4281715808 hasConcept C530470458 @default.
• W4281715808 hasConcept C71924100 @default.
• W4281715808 hasConcept C72563966 @default.
• W4281715808 hasConcept C90924648 @default.
• W4281715808 hasConcept C98274493 @default.
• W4281715808 hasConceptScore W4281715808C121608353 @default.
• W4281715808 hasConceptScore W4281715808C126322002 @default.
• W4281715808 hasConceptScore W4281715808C143998085 @default.
• W4281715808 hasConceptScore W4281715808C197934379 @default.
• W4281715808 hasConceptScore W4281715808C2775930923 @default.
• W4281715808 hasConceptScore W4281715808C2776256026 @default.
• W4281715808 hasConceptScore W4281715808C2776999253 @default.
• W4281715808 hasConceptScore W4281715808C2778496288 @default.
• W4281715808 hasConceptScore W4281715808C2778570526 @default.
• W4281715808 hasConceptScore W4281715808C2779438470 @default.
• W4281715808 hasConceptScore W4281715808C2779744173 @default.
• W4281715808 hasConceptScore W4281715808C29730261 @default.
• W4281715808 hasConceptScore W4281715808C530470458 @default.
• W4281715808 hasConceptScore W4281715808C71924100 @default.
• W4281715808 hasConceptScore W4281715808C72563966 @default.
• W4281715808 hasConceptScore W4281715808C90924648 @default.
• W4281715808 hasConceptScore W4281715808C98274493 @default.
• W4281715808 hasFunder F4320307765 @default.
• W4281715808 hasIssue "7" @default.
• W4281715808 hasLocation W42817158081 @default.

• next